Investor Onboarding
Join the Future of AI Health Innovation, Empowering the Consumer for Early Identification of Chronic Disease, Cancer and Improved Longevity, Health and Regenerative Health therapies with Clear Health Pass™ – A Groundbreaking Opportunity for Q4, 2024 Early Investors
2024 Investment Access prior to our Anticipated 2025 Public Exit with Expected 300-600% ROI: Gain access to our pre-IPO Series B round, with the potential for accelerated returns as Clear Health Pass™ targets a NASDAQ listing in early
2025. Early investors are uniquely positioned to benefit from our growth trajectory.
2025. Early investors are uniquely positioned to benefit from our growth trajectory.
Exclusive Alignment with Transformative Healthcare Innovation: Our CXO will
personally assess your investment goals, ensuring alignment with our mission to revolutionize diagnostics and wound care. This is a chance to be part of a high-impact company reshaping the future of healthcare.
personally assess your investment goals, ensuring alignment with our mission to revolutionize diagnostics and wound care. This is a chance to be part of a high-impact company reshaping the future of healthcare.
Insider Access and Priority Updates: As an investor, you’ll receive ongoing, exclusive
insights and priority updates on our expansion, product advancements, and market achievements, keeping you connected to Clear Health Pass™’s journey to public market success.